Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL646889 | 0.98 | CHRM2 (0.56) | CHRM2ALDH1A1RAB9APKMGAA | |
| SCHEMBL988592 | 0.84 | CHRM2 (0.62) | CHRM2ALDH1A1RAB9APKMGAA | |
| SCHEMBL121529 | 0.83 | CHRM2 (0.70) | CHRM2ALDH1A1PKMGAADPP7 | |
| SCHEMBL15662443 | 0.81 | CA12 (0.55) | ALDH1A1GAAKDM4EHTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2147064 | 0.81 | CHRM2 (0.68) | CHRM2ALDH1A1RAB9APKMGAA | |
| Hydrochloric Acid SCHEMBL9479560 | 0.81 | CHRM2 (0.68) | CHRM2ALDH1A1RAB9APKMGAA | |
| SCHEMBL7417749 | 0.81 | CHRM2 (0.58) | CHRM2ALDH1A1PKMGAADPP7 | |
| SCHEMBL22729788 | 0.81 | PYCR1 (0.61) | CHRM2ALDH1A1RAB9APKMGAA | |
| SCHEMBL2938432 | 0.79 | CHRM2 (0.78) | CHRM2ALDH1A1PKMGAAKDM4E | |
| SCHEMBL28674781 | 0.79 | LOXL2 (0.55) | CHRM2ALDH1A1RAB9APKMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109641915-B | Novel 4- (aryl) -N- (3-alkoxyfuro [2,3-B ] pyrazin-2-yl) -piperazine-1-carboxamide derivatives and their antiproliferative effect | LSK新药开发有限公司 | 2021-05-28 | — | — | CN | claimed |
| EP-3470417-B1 | NOVEL 4-(ARYL)-N-(3-ALKOXYFURO[2,3-B]PYRAZIN-2-YL)-PIPERAZINE-1-CARBOXAMIDE DERIVATIVE AND ANTIPROLIFERATIVE EFFECT THEREOF | LSK NRDO CO LTD (KR) | 2020-11-25 | — | — | EP | claimed |
| US-10800788-B2 | 4-(aryl)-N-(3-alkoxyfuro[2,3-b]pyrazin-2-yl)-piperazine-1-carboxamide derivative and antiproliferative effect thereof | LSK NRDO CO., LTD. (KR) | 2020-10-13 | — | — | US | claimed |
| US-20190337959-A1 | Novel 4-(Aryl)-N-(3-Alkoxyfuro[2,3-b]pyrazin-2-yl)-Piperazine-1-Carboxamide Derivative and Antiproliferative Effect Thereof | HLB LIFE SCIENCE R&D CO., LTD. (KR) | 2019-11-07 | — | — | US | claimed |
| EP-3470417-A1 | NOVEL 4-(ARYL)-N-(3-ALKOXYFURO[2,3-B]PYRAZIN-2-YL)-PIPERAZINE-1-CARBOXAMIDE DERIVATIVE AND ANTIPROLIFERATIVE EFFECT THEREOF | Dongguk University Industry-Academic Cooperation Foundation (KR) | 2019-04-17 | — | — | EP | claimed |
| CN-109641915-A | Novel 4- (aryl)-N- (3- alkoxy furans simultaneously [2,3-B] pyrazine -2- base)-piperazine -1- carboxamides derivatives and its antiproliferative effect | 东国大学校产学协力团 | 2019-04-16 | — | — | CN | claimed |
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-11-06 | — | — | US | disclosed |
| CN-119528923-A | Tri-fused ring compound and preparation method and application thereof | 韦恩生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4504739-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20250002495-A1 | SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME | TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) | 2025-01-02 | — | — | US | disclosed |
| US-12157736-B2 | Spiro-lactam NMDA modulators and methods of using same | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2024-12-03 | — | — | US | disclosed |
| US-12084444-B2 | Spiro-lactam NMDA modulators and methods of using same | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (CN) | 2024-09-10 | — | — | US | disclosed |
| WO-2024054919-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (CN) | 2024-03-14 | — | — | WO | disclosed |
| US-20090156557-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2008054956-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008045834-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| CN-1980904-A | CETP inhibitors | MERCK & CO INC (US) | 2007-06-13 | — | — | CN | disclosed |
| US-20070117816-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| US-20070117816-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| WO-2007044779-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337959-A1 | Novel 4-(Aryl)-N-(3-Alkoxyfuro[2,3-b]pyrazin-2-yl)-Piperazine-1-Carboxamide Derivative and Antiproliferative Effect Thereof | MKI67, API5, CCAR2 | CHRM2 4795/4885ALDH1A1 158/4885RAB9A 3788/4885 |
| US-20070117816-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | CHRM2 4747/4885ALDH1A1 4208/4885RAB9A 2395/4885 |
| US-10800788-B2 | 4-(aryl)-N-(3-alkoxyfuro[2,3-b]pyrazin-2-yl)-piperazine-1-carboxamide derivative and antiproliferative effect thereof | MKI67, AADAC, API5 | CHRM2 4830/4885ALDH1A1 94/4885RAB9A 3941/4885 |
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CHRM2 1207/4885ALDH1A1 3983/4885RAB9A 1642/4885 |
| US-20090156557-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | CHRM2 4827/4885ALDH1A1 3887/4885RAB9A 1914/4885 |
| US-12084444-B2 | Spiro-lactam NMDA modulators and methods of using same | GRIN1, GRIN2A, GRIN2C | CHRM2 639/4885ALDH1A1 2935/4885RAB9A 1381/4885 |
| US-20250002495-A1 | SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME | GRIN1, GRIN2A, GRIN2C | CHRM2 639/4885ALDH1A1 2935/4885RAB9A 1381/4885 |
| US-12157736-B2 | Spiro-lactam NMDA modulators and methods of using same | GRIN1, GRIN2A, GRIN2C | CHRM2 639/4885ALDH1A1 2935/4885RAB9A 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.